Kevin Moran
Net Worth

Last updated:

What is Kevin Moran net worth?

The estimated net worth of Mr. Kevin Moran is at least $4,596,206 as of 6 Sep 2025. He owns shares worth $1,053,424 as insider, has earned $520,262 from insider trading and has received compensation worth at least $3,022,520 in Cardinal Health, Inc. and Vanda Pharmaceuticals Inc..

What is the salary of Kevin Moran?

Mr. Kevin Moran salary is $755,630 per year as Senior Vice President, Chief Financial Officer & Treasurer in Vanda Pharmaceuticals Inc..

What stocks does Kevin Moran currently own?

As insider, Mr. Kevin Moran owns shares in one company:

Company Title Shares Price per share Total value
Vanda Pharmaceuticals Inc. (VNDA) Senior Vice President, Chief Financial Officer & Treasurer 231,014 $4.56 $1,053,424

What does Vanda Pharmaceuticals Inc. do?

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Kevin Moran insider trading

Vanda Pharmaceuticals Inc.

Mr. Kevin Moran has made 14 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 8,902 units of VNDA stock worth $37,415 on 5 Mar 2024.

The largest trade he's ever made was exercising 16,000 units of VNDA stock on 15 Jun 2023. As of 6 Sep 2025 he still owns at least 231,014 units of VNDA stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 8,902 $4.2 $37,415
Sale
Common Stock 5,798 $4.48 $25,981
Sale
Common Stock 1,800 $6.31 $11,349
Sale
Common Stock 412 $6.3 $2,596
Sale
Common Stock 16,000 $6.29 $100,704
Sale
Common Stock 5,968 $6.28 $37,497
Sale
Common Stock 7,966 $6.26 $49,843
Option
Common Stock 7,500 $3.12 $23,400
Sale
Common Stock 4,792 $10.61 $50,829
Option
Stock Option (Right to Buy) 7,500 $3.12 $23,400
Sale
Common Stock 2,239 $10.97 $24,562
Sale
Common Stock 8,832 $11.28 $99,651
Sale
Common Stock 3,473 $11.19 $38,863
Sale
Common Stock 2,130 $19.24 $40,973
Sale
Common Stock 6,044 N/A N/A
Sale
Common Stock 3,327 N/A N/A

Cardinal Health key executives

Cardinal Health, Inc. executives and other stock owners filed with the SEC: